Related Experiment Video
Updated: Apr 15, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Thyroxine in acute myocardial infarction (ThyrAMI) - levothyroxine in subclinical hypothyroidism post-acute
Avais Jabbar1, Lorna Ingoe2, Simon Pearce3,4
1Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK. avais.jabbar@ncl.ac.uk.
Insights
Subclinical hypothyroidism (SCH) in acute myocardial infarction (AMI) patients may increase cardiac mortality. These trials investigate if levothyroxine treatment improves cardiovascular outcomes in AMI patients with SCH.
Area of Science:
- Cardiology
- Endocrinology
- Clinical Trials
Background:
- Cardiac disease is a leading cause of death in the UK.
- Subclinical hypothyroidism (SCH) post-acute myocardial infarction (AMI) is linked to increased cardiac mortality.
- Thyroid hormone levels can impact cardiovascular health.
Purpose of the Study:
- To assess the association between thyroid function at AMI and cardiovascular outcomes (ThyrAMI 1).
- To evaluate the effect of levothyroxine on left ventricular (LV) function and vascular health in AMI patients with SCH (ThyrAMI 2).
Main Methods:
- ThyrAMI 1: A 24-month prospective observational study of AMI patients.
- ThyrAMI 2: A 12-month double-blinded, randomized placebo-controlled trial of levothyroxine in 100 AMI patients with SCH.
- Levothyroxine (25 mcg daily, adjusted for TSH 0.4-2.5 mU/L) or placebo, initiated within 21 days of AMI.
Main Results:
- Outcomes include the effect of levothyroxine on ventricular function, endothelial function, and blood rheology.
- Data collection ongoing for ThyrAMI 1 and ThyrAMI 2.
Conclusions:
- Evidence suggests SCH treatment may improve cardiovascular parameters.
- ThyrAMI 1 and ThyrAMI 2 aim to determine if thyroid hormone levels are a key target for improving cardiovascular outcomes in AMI patients.
Background:
Cardiac disease is the most common cause of morbidity and mortality in the United Kingdom. Even minor changes in thyroid hormone concentration may impact adversely on the cardiovascular system. Subclinical hypothyroidism (SCH) after admission for an acute cardiac problem has been associated with an increase in cardiac mortality and overall death. We have designed protocols for a prospective observational study to assess the association of thyroid function at the time of acute myocardial infarction (AMI) with cardiovascular outcomes, and a double-blinded randomised placebo-controlled trial of levothyroxine to evaluate its effect on LV function and vascular health.
Methods/Design:
ThyrAMI 1: This will be a prospective longitudinal observational study of patients with AMI that will be followed for 24 months to study the association between thyroid status at the time of AMI (within 24 hours of diagnosis) with vascular outcomes. ThyrAMI 2: This will be a prospective double-blinded randomised placebo-controlled trial of levothyroxine of 12 months duration in patients with AMI and SCH.
Setting:
Patients will be recruited from five hospitals in the North East of England.
Participants:
One hundred patients with thyroid function tests within the subclinical hypothyroid range upon admission with an AMI and no previous history of thyroid disease.
Intervention:
Levothyroxine will be administered at a starting dose of 25 mcg once daily, which will be increased at intervals if needed to maintain a TSH level between 0.4 to 2.5 mU/L, versus a placebo.
Randomisation:
Participants will be randomized with a computerised randomisation algorithm, stratified by type of MI (NSTEMI versus STEMI), in a 1:1 ratio to levothyroxine therapy or placebo (as container or bottle numbers), starting within 21 (+/- 7) days of AMI.
Blinding:
Assignment to either the LT4 or placebo arm will be double-blinded.
Outcomes:
The outcome will be the effect of levothyroxine on ventricular function, endothelial function and blood coagulability and rheology.
Discussion:
There is evidence to suggest that treatment of SCH can improve cardiovascular parameters. Therefore, ThyrAMI 1 and ThyrAMI 2 will be the first trials investigating SCH in AMI to give a better insight into whether thyroid hormone levels are a key target for improving cardiovascular outcomes.
Trial Registration:
ISRCTN number: ISRCTN52505169 . Date of registration: 09/01/2015.
More Related Videos
08:22In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
Published on: October 27, 2020
07:40Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
Published on: October 10, 2019
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:20Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:14Myocarditis III: Medical Management